Sionna Therapeutics (NASDAQ:SION) Research Coverage Started at Citizens Jmp

Citizens Jmp assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a research report released on Tuesday, MarketBeat reports. The brokerage issued a market outperform rating and a $63.00 price target on the stock.

SION has been the subject of several other research reports. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 target price on shares of Sionna Therapeutics in a research note on Monday, January 5th. Royal Bank Of Canada reissued an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Lifesci Capital started coverage on Sionna Therapeutics in a research report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 target price on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.63.

Sionna Therapeutics Price Performance

Sionna Therapeutics stock opened at $38.00 on Tuesday. Sionna Therapeutics has a 12 month low of $7.26 and a 12 month high of $45.00. The business has a 50 day simple moving average of $39.89 and a 200-day simple moving average of $34.81. The stock has a market capitalization of $1.70 billion and a PE ratio of -7.80.

Insider Buying and Selling at Sionna Therapeutics

In other news, major shareholder Tpg Gp A, Llc sold 250,000 shares of Sionna Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the sale, the insider directly owned 6,494,962 shares in the company, valued at approximately $259,798,480. This trade represents a 3.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter A. Thompson sold 33,356 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the sale, the director directly owned 3,561,655 shares in the company, valued at $158,671,730.25. This trade represents a 0.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 382,368 shares of company stock valued at $15,898,607. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Several large investors have recently bought and sold shares of the company. Invesco Ltd. purchased a new position in shares of Sionna Therapeutics in the fourth quarter valued at $4,573,000. XTX Topco Ltd acquired a new stake in Sionna Therapeutics in the 4th quarter valued at about $203,000. Superstring Capital Management LP purchased a new position in Sionna Therapeutics during the 4th quarter valued at about $7,430,000. Artia Global Partners LP acquired a new position in Sionna Therapeutics during the fourth quarter worth about $4,926,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Sionna Therapeutics in the fourth quarter valued at about $58,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.